NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Synthekine

Synthekine

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.synthekine.com/

Last Round

Series C

Jan 6, 2023

Total Funding Raised

$289.5M

Company Overview

Synthekine is a biotechnology company that develops engineered cytokine therapeutics aimed at creating disease-optimized treatments through targeted protein engineering and immunological insights for cancer and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cytokine therapeuticsprotein engineeringbiotechIL-2immunotherapybiased cytokine agonistssolid tumor treatmentIL-10drug discoveryclinical-stage biotechbiologicsimmune-modulating drugspharma pipelinenext-gen cytokinesprecision immunology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synthekine Comparables

Compare Synthekine with similar companies based on industry and business-model similarity.

Synthekine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asher Biotherapeutics
86%
Aulos Bioscience
85%
Bright Peak Therapeutics
84%

Synthekine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 6, 2023
Series BJun 10, 2021
Series ASep 17, 2020

Key People

Founding team and executive leadership

Greg Yedinak

Chief Technology Officer

Executive Team

Synthekine Investors

Notable investors and investment history

Synthekine investors
InvestorRounds
The Column GroupSeries B, Series C, Series A
Deerfield ManagementSeries C, Series B
Janus Henderson GroupSeries C, Series B
RA Capital ManagementSeries C, Series B
TCG CrossoverSeries B
Omega FundsSeries C, Series B
The Chernin GroupSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 31, 2025

    Presenting initial clinical data for STK-012 at SITC 2025.

  • Oct 31, 2025

    Initial data for STK-012 will be presented at SITC 2025.

Synthekine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Synthekine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synthekine's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range60
Year Founded2018
Last FundingJan 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.